Indoco Remedies

Indoco Remedies Forward P/E

The Forward P/E Ratio of Indoco Remedies (INDOCO.NS) as of Oct 16, 2026 is -18.91. In the previous year, Forward P/E Ratio was -25.31 — a change of -25.29% (higher).

Forward P/E

-18.91

YoY

-25.29%

Last updated:

Forward P/E Ratio of Indoco Remedies is 2026 -18.91 . Forward P/E Ratio of Indoco Remedies was 2025 -25.31 . It decreases by -25.29% higher compared to the previous year.

The Indoco Remedies Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-642.78 INR
Jan 1, 2020
77.40 INR
Jan 1, 2021
20.06 INR
Jan 1, 2022
12.06 INR
Jan 1, 2023
13.12 INR
Jan 1, 2024
18.96 INR
Jan 1, 2025
-25.31 INR
Jan 1, 2026
-18.91 INR
The Indoco Remedies Forward P/E history
YEARForward P/EYoY
-18.91-25.29%
-25.31-233.52%
18.96+44.47%
13.12+8.82%
12.06-39.89%
20.06-74.08%
77.40-112.04%
-642.78-1,517.39%
45.35+87.22%
24.22+7.68%
22.49-0.20%
22.54-29.98%
32.19—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indoco Remedies Stock analysis

What does Indoco Remedies do? Indoco Remedies Ltd, listed on the National Stock Exchange of India with ticker INDOCO.NS and ISIN INE873D01024, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It employs 6,101 full-time employees and went public via an IPO on January 7, 2005. Indoco Remedies Ltd focuses on the manufacturing and marketing of formulations, including finished dosage forms and active pharmaceutical ingredients (APIs). The company serves multiple therapeutic categories such as diabetology, respiratory care, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicine. Its product portfolio includes brands like Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel. The company caters to both domestic and international markets. Indoco Remedies Ltd has subsidiaries including Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited. The company's website is https://www.indoco.com/. Indoco Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indoco Remedies stock

Forward P/E Ratio of Indoco Remedies is -18.91 in 2026.

Forward P/E Ratio of Indoco Remedies changed from -25.31 to -18.91, representing a -25.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Indoco Remedies since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Indoco Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Indoco Remedies

All Key Metrics — Indoco Remedies